Cargando…
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
Dexamethasone, a corticosteroid, has been approved for use in the treatment of severe COVID-19, which is characterised by hyperinflammation and associated lung damage. However, dexamethasone shows no clinical benefit in the treatment of less severe disease, and prolonged treatment may lead to immuno...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390447/ https://www.ncbi.nlm.nih.gov/pubmed/34870152 http://dx.doi.org/10.1016/j.crphar.2021.100048 |